DE202014011208U1 - C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind - Google Patents

C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind Download PDF

Info

Publication number
DE202014011208U1
DE202014011208U1 DE202014011208.8U DE202014011208U DE202014011208U1 DE 202014011208 U1 DE202014011208 U1 DE 202014011208U1 DE 202014011208 U DE202014011208 U DE 202014011208U DE 202014011208 U1 DE202014011208 U1 DE 202014011208U1
Authority
DE
Germany
Prior art keywords
esterase inhibitor
composition
administration
hae
units
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE202014011208.8U
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viropharma Biologics LLC
Original Assignee
Shire Viropharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE202014011208(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Viropharma LLC filed Critical Shire Viropharma LLC
Publication of DE202014011208U1 publication Critical patent/DE202014011208U1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE202014011208.8U 2013-03-15 2014-03-17 C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind Expired - Lifetime DE202014011208U1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791399P 2013-03-15 2013-03-15
US201361791399P 2013-03-15

Publications (1)

Publication Number Publication Date
DE202014011208U1 true DE202014011208U1 (de) 2018-08-23

Family

ID=51538486

Family Applications (1)

Application Number Title Priority Date Filing Date
DE202014011208.8U Expired - Lifetime DE202014011208U1 (de) 2013-03-15 2014-03-17 C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind

Country Status (30)

Country Link
US (9) US9616111B2 (https=)
EP (3) EP3508213A1 (https=)
JP (9) JP6184581B2 (https=)
KR (4) KR20150135242A (https=)
CN (2) CN105517559A (https=)
AU (3) AU2014232912A1 (https=)
BR (1) BR112015023207A8 (https=)
CA (2) CA3054718A1 (https=)
CY (2) CY1119419T1 (https=)
DE (1) DE202014011208U1 (https=)
DK (2) DK3290046T3 (https=)
EA (1) EA201591278A1 (https=)
ES (2) ES2713004T3 (https=)
GB (1) GB2530921B (https=)
HK (1) HK1250912B (https=)
HR (2) HRP20171269T1 (https=)
HU (2) HUE041837T2 (https=)
IL (2) IL241549B (https=)
LT (2) LT3290046T (https=)
ME (2) ME03326B (https=)
MX (3) MX389449B (https=)
PL (2) PL3290046T3 (https=)
PT (2) PT3290046T (https=)
RS (2) RS58351B1 (https=)
SG (2) SG11201507616VA (https=)
SI (2) SI3290046T1 (https=)
SM (2) SMT201700415T1 (https=)
TR (1) TR201900319T4 (https=)
WO (1) WO2014145519A2 (https=)
ZA (3) ZA201507604B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58351B1 (sr) 2013-03-15 2019-03-29 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
EP4162947A1 (en) 2013-11-22 2023-04-12 Takeda Pharmaceutical Company Limited Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
US20180036394A1 (en) * 2015-02-20 2018-02-08 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
CN113999875A (zh) * 2015-05-28 2022-02-01 康奈尔大学 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法
CN108463243B (zh) * 2015-11-19 2022-06-14 夏尔人类遗传性治疗公司 重组人c1酯酶抑制剂及其用途
US20190175683A1 (en) * 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
US20190183991A1 (en) * 2016-08-23 2019-06-20 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
CN110769848A (zh) * 2017-05-16 2020-02-07 瑞士奥克特珐玛公司 C1-酯酶抑制剂制剂
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
CA3092163A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Treatment and prevention of pre-eclampsia
JP7788711B2 (ja) 2018-06-22 2025-12-19 株式会社Junten Bio 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法
US12139537B2 (en) 2018-06-22 2024-11-12 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
US12234287B2 (en) 2018-06-22 2025-02-25 Junten Bio Co., Ltd. Method for eliciting infectious immunological tolerance
WO2021124793A1 (ja) * 2019-12-16 2021-06-24 ニプロ株式会社 凝集防止剤ならびにそれを用いた医薬組成物および医療用デバイス
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
CN117120076A (zh) * 2021-01-27 2023-11-24 斯帕克治疗公司 用于治疗遗传性血管性水肿的组合物和方法
EP4366761A1 (en) 2021-07-09 2024-05-15 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms
KR20230046146A (ko) 2021-09-29 2023-04-05 주식회사 엘지에너지솔루션 배터리 제어 시스템 및 방법
WO2025090843A1 (en) * 2023-10-27 2025-05-01 Kansas State University Research Foundation Small-molecule inhibitors of c1s protease and classical complement pathway
CN119823254B (zh) * 2025-03-14 2025-06-03 深圳市卫光生物制品股份有限公司 一种c1酯酶抑制剂重组变体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
PT716611E (pt) 1993-09-01 2002-06-28 Sanquin Bloedvoorziening Metodo para reduzir a lesao do miocardio durante um enfarte do miocardio agudo
EP0868191A1 (en) 1995-12-18 1998-10-07 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
AT409336B (de) * 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
CA2398707C (en) 2000-01-31 2010-10-26 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
WO2004034971A2 (en) 2002-09-25 2004-04-29 The Center For Blood Research, Inc. Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
CN100431604C (zh) 2003-05-16 2008-11-12 法明知识产权股份有限公司 用于瞬时性治疗的具有短半衰期的c1抑制剂
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
CA2654440C (en) 2005-06-06 2013-09-03 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
JP5219819B2 (ja) 2005-10-21 2013-06-26 カタリスト・バイオサイエンシーズ・インコーポレイテッド 補体活性化を阻害する修飾プロテアーゼ
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
PT1965831E (pt) * 2005-12-21 2011-10-19 Pharming Intellectual Pty Bv Uso de inibidor c1 para a prevenção da lesão isquémia-reperfusão
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
CA2678001C (en) 2007-02-12 2017-07-11 Stefan Schulte Therapeutic application of kazal-type serine protease inhibitors
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US20100143325A1 (en) 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
DK2488203T3 (en) 2009-10-16 2017-03-13 Omeros Corp METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US9815876B2 (en) 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
US20130085111A1 (en) * 2010-03-18 2013-04-04 Thrombolytic Science, Llc Production of human c1 inhibitor in human cells
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
KR101956585B1 (ko) 2011-09-24 2019-03-11 체에스엘 베링 게엠베하 면역글로불린과 ｃ1-억제제를 사용하는 병용 치료요법
JP6127063B2 (ja) 2011-12-22 2017-05-10 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用
CA2867593A1 (en) 2012-03-16 2013-09-19 Belrose Pharma, Inc. Polymeric conjugates of c-1 inhibitors
EP2972375A2 (en) 2013-03-13 2016-01-20 Creatics LLC Methods and compositions for detecting pancreatic cancer
RS58351B1 (sr) * 2013-03-15 2019-03-29 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
JP6935245B2 (ja) * 2017-06-29 2021-09-15 大和ハウス工業株式会社 収容ラック
JP6889626B2 (ja) * 2017-06-29 2021-06-18 トキコシステムソリューションズ株式会社 燃料供給システム

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Carter et al. (1988) Eur. J. Biochem., 173 : 163). Im Plasma ist der C1-Esterasehemmer ein stark glycosyliertes Glycoprotein mit ungefähr 76 kDa (Perkins et al. (1990) J. Mol. Biol., 214:751). Die Aktivität eines C1-Esterasehemmers kann durch bekannte Verfahren erfasst werden (siehe z.B. Drouet et al. (1988) Clin. Chim. Acta., 174:121-30
Kibbe, et al., Eds., Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, Washington beschrieben
Zuraw et al. (2000) J. Allergy Clin. Immunol. 105: 541-546; Bowen et al. (2001) Clin. Immunol. 98: 157-163
Zuraw, B.L. (2008) N. Engl. J. Med., 359: 1027- 1036

Also Published As

Publication number Publication date
JP2019073546A (ja) 2019-05-16
US20200261556A1 (en) 2020-08-20
JP6473534B2 (ja) 2019-02-20
JP6877470B2 (ja) 2021-05-26
JP2019073545A (ja) 2019-05-16
PL2968434T3 (pl) 2018-01-31
AU2018229558B2 (en) 2020-03-05
RS56285B1 (sr) 2017-12-29
US10201595B2 (en) 2019-02-12
US20180110843A1 (en) 2018-04-26
EA201591278A1 (ru) 2016-03-31
US20170224788A1 (en) 2017-08-10
JP6877472B2 (ja) 2021-05-26
CA2904543C (en) 2019-10-08
KR102430453B1 (ko) 2022-08-05
NZ710730A (en) 2021-07-30
US10130690B2 (en) 2018-11-20
TR201900319T4 (tr) 2019-02-21
AU2020203183A1 (en) 2020-06-04
LT3290046T (lt) 2019-03-12
JP2017105847A (ja) 2017-06-15
PL3290046T3 (pl) 2019-05-31
WO2014145519A3 (en) 2014-12-31
KR20210129267A (ko) 2021-10-27
GB2530921B (en) 2017-09-20
ME03326B (me) 2019-10-20
EP2968434A4 (en) 2016-03-02
HK1250912B (en) 2020-01-10
KR102579789B1 (ko) 2023-09-15
US20180153972A1 (en) 2018-06-07
KR20220070049A (ko) 2022-05-27
RS58351B1 (sr) 2019-03-29
EP3290046A1 (en) 2018-03-07
PT3290046T (pt) 2019-02-18
MX2020004724A (es) 2022-01-18
HUE041837T2 (hu) 2019-05-28
CY1121653T1 (el) 2020-07-31
ZA201806793B (en) 2020-01-29
CN111529708A (zh) 2020-08-14
US11364288B2 (en) 2022-06-21
SI2968434T1 (sl) 2017-11-30
SI3290046T1 (sl) 2019-04-30
ES2639833T3 (es) 2017-10-30
JP6877471B2 (ja) 2021-05-26
HK1220403A1 (en) 2017-05-05
JP2018119000A (ja) 2018-08-02
JP6473536B2 (ja) 2019-02-20
US20160015795A1 (en) 2016-01-21
KR20150135242A (ko) 2015-12-02
EP3290046B1 (en) 2019-01-02
SMT201700415T1 (it) 2017-11-15
ZA201507604B (en) 2018-05-30
CA3054718A1 (en) 2014-09-18
IL276153B (en) 2022-06-01
MX2021011946A (es) 2021-11-17
CA2904543A1 (en) 2014-09-18
GB201519921D0 (en) 2015-12-23
ME02865B (me) 2018-04-20
DK2968434T3 (en) 2017-09-11
HUE036224T2 (hu) 2018-06-28
AU2014232912A1 (en) 2015-09-03
NZ751555A (en) 2021-07-30
JP6473535B2 (ja) 2019-02-20
JP2019073544A (ja) 2019-05-16
JP6422520B2 (ja) 2018-11-14
HRP20190270T1 (hr) 2019-04-05
GB2530921A (en) 2016-04-06
JP2021088599A (ja) 2021-06-10
IL241549B (en) 2020-08-31
JP2016516073A (ja) 2016-06-02
WO2014145519A2 (en) 2014-09-18
US11534482B2 (en) 2022-12-27
MX389449B (es) 2025-03-20
HRP20171269T1 (hr) 2017-11-03
CN105517559A (zh) 2016-04-20
JP2018119002A (ja) 2018-08-02
EP2968434A2 (en) 2016-01-20
JP2018119001A (ja) 2018-08-02
US20180110844A1 (en) 2018-04-26
ES2713004T3 (es) 2019-05-17
JP6184581B2 (ja) 2017-08-23
SG11201507616VA (en) 2015-10-29
KR20210021146A (ko) 2021-02-24
CY1119419T1 (el) 2018-03-07
PT2968434T (pt) 2017-09-18
AU2018229558A1 (en) 2018-10-04
EP3508213A1 (en) 2019-07-10
US20180085441A1 (en) 2018-03-29
BR112015023207A8 (pt) 2018-01-23
DK3290046T3 (en) 2019-03-18
MX373965B (es) 2020-07-13
SG10201707598QA (en) 2017-10-30
IL276153A (en) 2020-09-30
US10080788B2 (en) 2018-09-25
US20190160158A1 (en) 2019-05-30
US10105423B2 (en) 2018-10-23
SMT201900141T1 (it) 2019-05-10
AU2020203183B2 (en) 2022-06-02
US20190160157A1 (en) 2019-05-30
BR112015023207A2 (pt) 2017-11-21
ZA201706929B (en) 2019-05-29
EP2968434B1 (en) 2017-06-28
US9616111B2 (en) 2017-04-11
MX2015011281A (es) 2016-03-03
LT2968434T (lt) 2017-09-25

Similar Documents

Publication Publication Date Title
DE202014011208U1 (de) C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind
DE69618018T2 (de) Arzneimittel enthaltend botulinum toxin oder neurotoxin und herstellungsverfahren
EP1455824B1 (de) Lyophilisierte zubereitung enthaltend antikörper gegen den egf-rezeptor
EP0674525B1 (de) Lagerstabile wässrige pharmazeutische zubereitungen von g-csf
EP0876140B1 (de) Verbesserte kontrastmittenlösungen für die intravasale anwendung
DE10355251A1 (de) Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
DD298053A5 (de) Verfahren zum herstellen einer stabilen zubereitung eines pharmazeutischen peptides
DE102004030409A1 (de) Neue Verwendung von Meloxicam in der Veterinärmedizin
HUE033949T2 (hu) Nátrium klorid oldat gyógyszer újraoldására vagy hígítására
DE69717293T2 (de) Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form
EP2679239A1 (de) Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
DE69420872T2 (de) Hgh enthaltende pharmazeutische zubereitungen
EP0602686B1 (de) Lektinkonzentrate aus Mistelextrakten und entsprechende standardisierte, stabilisierte Mistellektinpräparate, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel und deren Verwendung zur Erhöhung der natürlichen Immunresistenz und/oder in der Tumor-Therapie
DE69101784T2 (de) Stabilisierte zusammensetzung enthaltend ein fibroblastwachstumsfaktor.
DE69832165T2 (de) Hgf zur behandlung von akutem nierenversagen
DE69129563T2 (de) Epidermis-Wachstumsfaktor als Arzneimittel zur Wiederherstellung der Neuronen der Substantia nigra in der Behandlung nervenzerstörender Störungen
EP1435914B1 (de) Stabile galenische gefriergetrocknete arzneimittelzubereitung von rekombinanten carbohydratbindenden polypeptiden
DE69209486T2 (de) Stabilisierte pharmaceutische Zusammensetzung die nicht-glycozylierte, reduzierte rekombinante human IL-2 umfasst und Verfahren zu ihrer Herstellung
EP0869811B1 (de) Immunologisch wirksame mistelextraktzubereitungen
WO2001045743A2 (de) Verwendung eines enzyms zur verbesserung der geweberesorption von arzneimitteln
DE202017103487U1 (de) Osmolyt in Kombination mit lipophiler Grundlage
DE19957371A1 (de) Mitomycin C-Lösung
DE102025101336A1 (de) Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse
HK40010873A (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency

Legal Events

Date Code Title Description
R150 Utility model maintained after payment of first maintenance fee after three years
R207 Utility model specification
R151 Utility model maintained after payment of second maintenance fee after six years
R152 Utility model maintained after payment of third maintenance fee after eight years
R071 Expiry of right